久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

美國Abraxis BioScience
美國ABRAXIS公司一個完全集成的生物技術公司，致力于提供先進療法，如納米制劑，以及核心技術，為病人提供醫療專業人員和更安全和更有效的治療癌癥和其他疾病的關鍵。 

 Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics, such as ABRAXANE, and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses.

Abraxis' portfolio includes the world's first and only protein-based nanoparticle chemotherapeutic compound. Scientists at Abraxis developed its proprietary tumor targeting system known as the nab? Technology platform, an innovative approach to treating cancer and other critical illnesses. By harnessing the unique natural properties of the human protein albumin, Abraxis' nab technology platform enables the transport and delivery of therapeutic agents to the site of disease. This revolutionary biologically interactive delivery system is being further developed with other water insoluble drugs for their potential use across a broad range of tumors.

ABRAXANE? for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), the first U.S. Food and Drug Administration (FDA) approved product to use the nab platform, was launched in 2005 for the treatment of metastatic breast cancer.

From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company's pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them.